About Uncommon
Uncommon is a company based in Cambridge (United Kingdom) founded in 2017 by Benjamina Bollag and Ruth Faram was acquired by Meatable in August 2025. It operates as a HealthTech. Uncommon has raised $30 million across 1 funding round from investors including Meatable, Balderton Capital and Redalpine. Uncommon offers products and services including SymphoRNA. Uncommon operates in a competitive market with competitors including ENOUGH, VFC Foods, Ivy Farm, Adamo Foods and Roslin Technologies, among others.
- Headquarter Cambridge, United Kingdom
- Founders Benjamina Bollag, Ruth Faram
-
Sectors
Consumer
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Uncommon
Uncommon offers a comprehensive portfolio of products and services, including SymphoRNA.
A platform for nucleic acid delivery technology.
Funding Insights of Uncommon
Uncommon has successfully raised a total of $30M through 1 strategic funding round. The most recent funding activity was a Series A round of $30 million completed in June 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Uncommon
Uncommon has secured backing from 7 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Meatable, Balderton Capital and Redalpine.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage investments are directed toward ICT and health tech startups.
|
Locked | Locked | Locked | |
|
Multistage venture capital investments are focused on technology sectors.
|
Locked | Locked | Locked | |
|
Venture capital fund focused on tech startups
|
Locked | Locked | Locked |
Investor details for Uncommon
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Uncommon
Investment portfolio details for Uncommon
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Uncommon
Detailed financials for Uncommon
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Uncommon Comparisons
Peer comparison for Uncommon
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Uncommon
Uncommon operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ENOUGH, VFC Foods, Ivy Farm, Adamo Foods and Roslin Technologies, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Fungi-based meat substitutes are developed under the ENOUGH brand.
|
|
| Locked | Locked | Locked |
Provider of plant-based food products to replace meat
|
|
| Locked | Locked | Locked |
Cultivated plant-based meat products are developed by Ivy Farm.
|
|
| Locked | Locked | Locked |
Fungi-based meat substitute products are developed by Adamo Foods.
|
|
| Locked | Locked | Locked |
Livestock biotechnology solutions for avian species are provided.
|
Detailed competitors of Uncommon
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Uncommon
Complete news archive for Uncommon
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Uncommon
Uncommon was founded in 2017 and raised its 1st funding round 6 years after it was founded.
Uncommon is headquartered in Cambridge, United Kingdom. It is registered at Cambridge, Cambridgeshire, United Kingdom.
Benjamina Bollag is the current CEO of Uncommon. They have also founded this company.
Uncommon is a funded company, having raised a total of $30M across 1 funding round to date.
Uncommon is engaged in developing advanced nucleic acid delivery technology through its SymphoRNA platform. The company has transitioned from its previous cultivated platform, which was sold to Vow and Meatable, to focus on innovative solutions in the biotechnology sector. Its efforts are directed towards creating impactful health technology solutions.
Uncommon's top competitors include Quorn Foods, Roslin Technologies and ENOUGH.
Uncommon offers SymphoRNA.
Uncommon has 7 investors. Key investors include Meatable, Balderton Capital, Redalpine, East Alpha, and Lowercarbon Capital.